- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00523133
Research on Individualized Treatment for Alcoholism (RITA)
August 30, 2007 updated by: Indiana University School of Medicine
Posttreatment Effects of Naltrexone
The purpose of this study was to compare the effects of two psychosocial treatments that differed in scope and intensity (Broad Spectrum Treatment and Motivational Enhancement Treatment) combined with 3 or 6 months of treatment with naltrexone on alcohol drinking behaviors in alcohol dependent patients.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
185
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- University Hospital, Psychiatry Outpatient Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- men and women between the ages of 21-65
- current DSM-IV diagnosis of alcohol dependence
- abstinent for a minimum of 3 and maximum of 21 days prior to treatment initiation
- able to participate in an 18-month outpatient study
- live within a one hour or less commute to Fairbanks
- fluent in English
- women of child-bearing potential must have a negative pregnancy test and use effective contraceptive methods.
- score as contemplators or greater on the Readiness For Change Scale
Exclusion Criteria:
- severe hepatic disease (gGGT, SGOT or other liver functions greater than 4 times normal)
- opiate use (for any reason) in the last 14 days or a history of opioid dependence in the past year
- pregnant or lactating females or those unwilling to use birth control
- inability, according to the opinion of the interviewer, to follow medication instructions and safety precautions
- comorbid substance dependence (but not abuse) diagnosis in the past 6 months, excluding nicotine or marijuana dependence
- concomitant use of medications intended to decrease drinking (e.g. disulfiram)
- meeting current DSM criteria for bipolar disorder, schizophrenia, bulimia/anorexia, dementia, major depression
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent Days Abstinent
Time Frame: 18 months
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent Heavy Drinking Days
Time Frame: 18 months
|
18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Dena Davidson, PhD, Indiana University School of Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2000
Study Completion (Actual)
July 1, 2005
Study Registration Dates
First Submitted
August 30, 2007
First Submitted That Met QC Criteria
August 30, 2007
First Posted (Estimate)
August 31, 2007
Study Record Updates
Last Update Posted (Estimate)
August 31, 2007
Last Update Submitted That Met QC Criteria
August 30, 2007
Last Verified
August 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R01AA012696-01A1 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Dependence
-
BrainswayRecruitingAlcohol Dependence | Alcoholism | Alcohol Use Disorder | Alcohol Abuse | Alcohol Addiction | Alcohol Abuse/DependenceUnited States, Israel
-
University Hospital, LilleCompleted
-
Tel-Aviv Sourasky Medical CenterMinistry of Health, IsraelUnknownAlcohol-dependenceIsrael
-
National Institute on Alcohol Abuse and Alcoholism...CompletedAlcohol Abuse | Alcohol Dependence (Primary Condition)United States
-
Pop Test Oncology LLCBaylor College of Medicine; Michael E. DeBakey VA Medical Center; Congressionally... and other collaboratorsCompletedPotential Treatment for Alcohol Dependence-Alcohol InteractionUnited States
-
University Hospital, Gentofte, CopenhagenCompleted
-
Massachusetts General HospitalCompletedAlcohol Dependence | Drug Abuse | Alcohol Abuse | Drug DependenceUnited States
-
University of WashingtonU.S. Army Medical Research and Development CommandCompletedAlcohol Dependence | Substance Abuse | Alcohol Abuse | Substance DependenceUnited States
-
Anders Fink-Jensen, MD, DMSciThe Novavì outpatient clinics, Copenhagen; Neurobiology Research Unit, Rigshospitalet... and other collaboratorsCompletedAddiction, Alcohol | Alcohol Dependence, in RemissionDenmark
-
Psychiatric Centre RigshospitaletThe Novavì outpatient clinics, CopenhagenRecruitingAddiction, Alcohol | Alcohol Dependence, in RemissionDenmark
Clinical Trials on naltrexone
-
Mayo ClinicUniversity of TorontoRecruitingObesity | Weight Loss | Schizo Affective Disorder | Bipolar I Disorder | Bipolar II Disorder | GLP - 1United States
-
University of Alabama at BirminghamNational Institute of Neurological Disorders and Stroke (NINDS)Not yet recruitingMyalgic Encephalomyelitis/Chronic Fatigue SyndromeUnited States
-
Yale UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcohol Dependence | Human Immunodeficiency Virus | AIDS | Hazardous Drinking | Problem DrinkingUnited States
-
Alkermes, Inc.Terminated
-
Alkermes, Inc.Completed
-
Shenzhen Sciencare Medical Industries Co., Ltd.Completed
-
Alkermes, Inc.Completed
-
San Diego State UniversityNational Institute on Drug Abuse (NIDA)RecruitingPlacebo | NaltrexoneUnited States
-
University of PennsylvaniaNational Institute on Drug Abuse (NIDA); St. Petersburg State Pavlov Medical...CompletedOpioid-Related Disorders | Heroin DependenceUnited States, Russian Federation
-
Medical University of LublinRecruitingQuality of Life | Vulvodynia | NaltrexonePoland